[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
EuropaOne-OffSalud y medicinaCiencia2mManifold MarketsSin KYCDatos de resolución verificadosCalibración aceptableAviso de calidad de datosDatos de la fuente degradados
Datos del 23 oct 2026, 20:35 UTC · política pm-quality-4
Pronóstico comunitario actualNo 90.2%
Pronosticadores
29
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 4 horas
Desactualizado6 ene 26, 22:51 UTC31 dic 26, 23:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsWill GiveWell research gene-editing mosquitoes to eradicate malaria?
Manifold MarketsWhen will there be a confirmation* of an adult human, whose IQ score was improved by 15 by gene-editing?
Manifold MarketsThere will be more children born via artificial wombs than not in first world countries before 2050
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsReglas
(https://www.metaculus.com/questions/embed/41169) Resolves according to Metaculus resolution.
- Metaculus high-level description: This question will resolve as Yes if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other than sickle cell disease and beta thalassemia before January 1, 2027.
